An EGFR signature predicts cell line and patient sensitivity to multiple tyrosine kinase inhibitors

EGFR is an oncogene with a high frequency of activating mutations in nonsmall cell lung cancer (NSCLC). EGFR inhibitors have been FDA‐approved for NSCLC and have shown efficacy in patients with certain EGFR mutations. However, only 9% to 26% of these patients achieve objective responses. In our stud...

Ausführliche Beschreibung